TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tango Therapeutics ( (TNGX) ) has provided an update.
On November 21, 2025, Tango Therapeutics entered into a Sales Agreement with Leerink Partners LLC to sell up to $100 million of its common stock through an at-the-market offering. This move follows the termination of a previous sales agreement with Jefferies LLC, effective the same day, indicating a shift in the company’s strategy for raising capital.
The most recent analyst rating on (TNGX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.
Spark’s Take on TNGX Stock
According to Spark, TipRanks’ AI Analyst, TNGX is a Neutral.
Tango Therapeutics’ stock score is primarily influenced by its financial performance, which highlights strong revenue growth but significant profitability challenges. The technical analysis indicates a bullish trend, providing some positive momentum. However, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation, resulting in a moderate overall score.
To see Spark’s full report on TNGX stock, click here.
More about Tango Therapeutics
Tango Therapeutics, Inc. operates in the biotechnology industry, focusing on developing targeted cancer therapies. The company specializes in identifying and targeting genetic vulnerabilities in cancer cells to create effective treatments.
Average Trading Volume: 2,984,847
Technical Sentiment Signal: Buy
Current Market Cap: $1.12B
For detailed information about TNGX stock, go to TipRanks’ Stock Analysis page.